Recursion Pharmaceuticals (RXRX) Free Cash Flow Growth (1y) (2021 - 2026)
Recursion Pharmaceuticals (RXRX) Free Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | 7.12% |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.27 Bn | 467.47 Bn | 1.35 Bn | 1,092.51% |
| 5 | Vertex Pharmaceuticals | 122.18 Bn | 114.93 Bn | 2.59 Bn | 66.37% |
| 6 | Regeneron Pharmaceuticals | 70.08 Bn | 61.32 Bn | 3.31 Bn | 3.98% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | 137.65% |
| 10 | Recursion Pharmaceuticals | 1.62 Bn | 957.04 Mn | -6.02 Mn | 39.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 39.19% |
| Dec 31, 2025 | 65.01% |
| Sep 30, 2025 | -72.11% |
| Jun 30, 2025 | 1.66% |
| Mar 31, 2025 | -22.80% |
| Dec 31, 2024 | -35.68% |
| Sep 30, 2024 | 2.52% |
| Jun 30, 2024 | -22.18% |
| Mar 31, 2024 | -38.81% |
| Dec 31, 2023 | -103.65% |
| Sep 30, 2023 | -36.39% |
| Jun 30, 2023 | -1.37% |
| Mar 31, 2023 | -207.45% |
| Dec 31, 2022 | 35.62% |
| Sep 30, 2022 | -25.04% |
| Jun 30, 2022 | -4.91% |
| Mar 31, 2022 | 332.19% |
| Dec 31, 2021 | -1,443.06% |
| Sep 30, 2021 | -110.80% |
| Jun 30, 2021 | -225.12% |